2026. INVESTIGATION OF MODIFIED SORAFENIB DERIVATIVES AS A TYROSINE KINASE INHIBITORS OF LEUKIMIA VIA MOLECULAR DOCKING. Frontier in Medical and Health Research. 4, 5 (May 2026), 567–585.